MA49673B1 - Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer - Google Patents

Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer

Info

Publication number
MA49673B1
MA49673B1 MA49673A MA49673A MA49673B1 MA 49673 B1 MA49673 B1 MA 49673B1 MA 49673 A MA49673 A MA 49673A MA 49673 A MA49673 A MA 49673A MA 49673 B1 MA49673 B1 MA 49673B1
Authority
MA
Morocco
Prior art keywords
combination
cancer
annulene
palbociclib
oxyphenyl
Prior art date
Application number
MA49673A
Other languages
English (en)
Other versions
MA49673A (fr
Inventor
Monsif Bouaboula
Maysoun Shomali
Fangxian Sun
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA49673A publication Critical patent/MA49673A/fr
Publication of MA49673B1 publication Critical patent/MA49673B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une combinaison de palbociclib et d'acide 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphényl]-8,9-dihydro-7h-benzo [7]annulène-2-carboxylique ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique contenant une telle combinaison, et les utilisations thérapeutiques de celle-ci, en particulier pour le traitement du cancer, y compris le cancer du sein.
MA49673A 2017-07-25 2018-07-23 Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer MA49673B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305998.1A EP3434272A1 (fr) 2017-07-25 2017-07-25 Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
PCT/EP2018/069901 WO2019020559A1 (fr) 2017-07-24 2018-07-23 Combinaison comprenant du palbociclib et de l'acide 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphényl]-8,9-dihydro-7h-benzo [7]annulène-2-carboxylique et son utilisation pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA49673A MA49673A (fr) 2021-03-24
MA49673B1 true MA49673B1 (fr) 2022-02-28

Family

ID=59569252

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49673A MA49673B1 (fr) 2017-07-25 2018-07-23 Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer

Country Status (30)

Country Link
US (2) US11260057B2 (fr)
EP (2) EP3434272A1 (fr)
JP (1) JP6741897B1 (fr)
KR (1) KR20200031622A (fr)
CN (1) CN111107851B (fr)
AR (1) AR112284A1 (fr)
AU (1) AU2018308871A1 (fr)
BR (1) BR112020001398A2 (fr)
CA (1) CA3070754A1 (fr)
CO (1) CO2020000240A2 (fr)
DK (1) DK3658147T3 (fr)
ES (1) ES2906279T3 (fr)
HR (1) HRP20212030T1 (fr)
HU (1) HUE057271T2 (fr)
IL (1) IL272166B2 (fr)
LT (1) LT3658147T (fr)
MA (1) MA49673B1 (fr)
MX (1) MX393852B (fr)
MY (1) MY195271A (fr)
PH (1) PH12020500091A1 (fr)
PL (1) PL3658147T3 (fr)
PT (1) PT3658147T (fr)
RS (1) RS62837B1 (fr)
RU (1) RU2764116C2 (fr)
SG (1) SG11202000367RA (fr)
SI (1) SI3658147T1 (fr)
TW (1) TWI768087B (fr)
UY (1) UY37818A (fr)
WO (1) WO2019020559A1 (fr)
ZA (1) ZA202000145B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (fr) * 2017-07-25 2019-01-30 Sanofi Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
ES2923412T3 (es) * 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
AU2020268762A1 (en) * 2019-05-09 2021-12-02 Sanofi 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
JP7680438B2 (ja) 2019-10-01 2025-05-20 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) * 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
AU2021366223A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US12595230B2 (en) 2020-10-19 2026-04-07 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202302084A (zh) * 2021-03-02 2023-01-16 法商賽諾菲公司 以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR102815360B1 (ko) 2022-03-03 2025-06-02 인하대학교 산학협력단 암의 예방 또는 치료용 조성물
US12558428B2 (en) 2024-03-08 2026-02-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105655A1 (fr) 1991-03-08 1992-09-09 Kent Neuenschwander Inhibiteurs de la squalene synthetase, a base de composes polyaromatiques renfermant une amine tertiaire
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es) 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
CZ2004220A3 (cs) 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
CA2512000C (fr) 2002-12-26 2011-08-09 Eisai Co., Ltd. Modulateurs selectifs des recepteurs d'oestrogene
AU2005267385B2 (en) 2004-06-25 2011-11-10 Janssen Pharmaceutica N.V. Quaternary salt CCR2 antagonists
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (fr) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Dérivés de benzocycloheptanes en tant qu'oestrogènes actifs de manière sélective
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9540361B2 (en) 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
KR20150039705A (ko) 2011-12-30 2015-04-13 켄타우루스 바이오파마 컴퍼니 리미티드 신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
SI3033086T1 (sl) * 2013-08-14 2022-01-31 Novartis Ag Kombinirana terapija za zdravljenje raka
WO2015028409A1 (fr) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft Dérivés de 6,7-dihydro-5h-benzo[7]annulène, procédé pour les préparer, préparations pharmaceutiques les contenant et leur utilisation pour fabriquer des médicaments
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2016146591A1 (fr) * 2015-03-16 2016-09-22 Astrazeneca Ab Traitement de combinaison
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
KR102676629B1 (ko) * 2015-04-29 2024-06-18 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN106924210A (zh) * 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
AU2017221083B2 (en) * 2016-02-15 2021-06-24 Sanofi 6,7-dihydro-5H-benzo[7]annulene derivatives as estrogen receptor modulators
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (fr) * 2017-07-25 2019-01-30 Sanofi Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
ES2923412T3 (es) 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
US20200155521A1 (en) * 2018-11-16 2020-05-21 Arqule, Inc. Pharmaceutical combination for treatment of cancer

Also Published As

Publication number Publication date
JP6741897B1 (ja) 2020-08-19
MX393852B (es) 2025-03-24
KR20200031622A (ko) 2020-03-24
RU2020107416A3 (fr) 2021-08-25
UY37818A (es) 2020-08-31
HUE057271T2 (hu) 2022-04-28
CO2020000240A2 (es) 2020-04-24
ES2906279T3 (es) 2022-04-18
BR112020001398A2 (pt) 2020-07-28
PT3658147T (pt) 2022-02-02
MA49673A (fr) 2021-03-24
PH12020500091A1 (en) 2020-09-14
CA3070754A1 (fr) 2019-01-31
IL272166B2 (en) 2023-04-01
EP3658147B1 (fr) 2021-11-10
US20220362248A1 (en) 2022-11-17
AU2018308871A1 (en) 2020-02-06
ZA202000145B (en) 2021-07-28
TW201919612A (zh) 2019-06-01
DK3658147T3 (da) 2022-01-31
SG11202000367RA (en) 2020-02-27
MY195271A (en) 2023-01-11
US20200171033A1 (en) 2020-06-04
RU2020107416A (ru) 2021-08-25
PL3658147T3 (pl) 2022-03-07
AR112284A1 (es) 2019-10-09
EP3658147A1 (fr) 2020-06-03
WO2019020559A1 (fr) 2019-01-31
US11260057B2 (en) 2022-03-01
LT3658147T (lt) 2022-01-10
CN111107851A (zh) 2020-05-05
RU2764116C2 (ru) 2022-01-13
RS62837B1 (sr) 2022-02-28
EP3434272A1 (fr) 2019-01-30
SI3658147T1 (sl) 2022-02-28
IL272166A (en) 2020-03-31
JP2020526572A (ja) 2020-08-31
HRP20212030T1 (hr) 2022-04-01
TWI768087B (zh) 2022-06-21
IL272166B (en) 2022-12-01
CN111107851B (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MA56748B1 (fr) Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MX2023006020A (es) Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA34559B1 (fr) Formulation pour le traitement du cancer
MA56038B1 (fr) Inhibiteurs à petite molécule de kinase induisant nf-kb
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
FR3065371B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
MA51612A (fr) Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille